HLN

Haleon plc
NYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$40.55B
P/E Ratio
19.21
EPS
$0.48
Beta
0.24
52W High
$11.06
52W Low
$8.59
50-Day MA
$9.76
200-Day MA
$9.82
Dividend Yield
2.15%
Profit Margin
14.50%
Forward P/E
15.70
PEG Ratio
2.15

About Haleon plc

Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$11.15B
Gross Profit (TTM)$7.31B
EBITDA$2.85B
Operating Margin23.90%
Return on Equity10.10%
Return on Assets5.08%
Revenue/Share (TTM)$2.50
Book Value$4.93
Price-to-Book1.85
Price-to-Sales (TTM)3.64
EV/Revenue3.366
EV/EBITDA13.36
Quarterly Earnings Growth (YoY)-4.50%
Quarterly Revenue Growth (YoY)2.20%
Shares Outstanding$4.40B
Float$4.43B
% Insiders0.01%
% Institutions13.65%

Historical Volatility

HV 10-Day
21.63%
HV 20-Day
22.65%
HV 30-Day
21.50%
HV 60-Day
23.36%
HV Rank
52.0%

Volatility is currently expanding

Analyst Ratings

Consensus ($11.93 target)
2
Strong Buy
1
Buy
2
Hold

Latest News

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three months to September, below Visible Alpha consensus of 3.5% and broadly unchanged from the second quarter.

Proactive Investors9/25/2026Negative
Deutsche Bank stays bearish on Haleon as growth headwinds mount

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include Sensodyne and Panadol, against a last close of 342.8p.

Proactive Investors9/23/2026Negative
LCUT or HLN: Which Is the Better Value Stock Right Now?

Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research9/11/2026Neutral
LCUT vs. HLN: Which Stock Is the Better Value Option?

Investors interested in Consumer Products - Discretionary stocks are likely familiar with Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research8/26/2026Positive
Jefferies raises Haleon price target to 410p on margin strength

Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.

Proactive Investors8/24/2026Positive
Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer"). The Tender Offer has been made upon the terms and subject to the conditions set forth in the Offer to Purchase dated 11 August 2026 (the "Offer to Purchase").

PRNewsWire8/19/2026Neutral
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes

LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrued Interest (each as defined below) (the "Tender Offer").

PRNewsWire8/11/2026Neutral
ACCO vs. HLN: Which Stock Is the Better Value Option?

Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Acco Brands (ACCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research8/4/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HLN and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026